{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:52:43Z","timestamp":1781711563809,"version":"3.54.5"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"\n Importance<\/jats:title>\n \n Lifileucel is a first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced\/metastatic melanoma with progression after anti\u2013programmed cell death protein 1 (PD-1) therapy and\/or BRAF inhibitor therapy, if\n BRAF<\/jats:italic>\n V600 mutations are present. In the C-144-01 phase 2 trial of lymphodepleting chemotherapy, lifileucel, and interleukin 2 (IL-2), cutaneous eruption occurred in 37.2% of individuals. These eruptions remain clinically and prognostically unknown.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine cutaneous toxic effects development in the setting of lifileucel therapy, abstract clinical and histopathologic eruption features, and test for association with objective radiographic tumor response.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective cohort study was performed at Mass General Brigham (MGB)\/Dana-Farber Cancer Institute (DFCI) that included all patients treated with lifileucel, outside of active clinical trials. The analysis was completed in December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n All individuals received cyclophosphamide\/fludarabine lymphodepletion, lifileucel, and 6 or fewer IL-2 infusions. Demographics, melanoma-specific factors (M stage, pre-TIL lactate dehydrogenase levels, and number of lines of prior systemic therapy), number of IL-2 doses received, eruption features, photography, and dermatopathologic findings were abstracted.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Radiographic responses 30 to 41 days, 42 to 89 days, and 90 days or longer from TIL infusion per Response Evaluation Criteria in Solid Tumors (RECIST) were abstracted. Individuals were stratified as high IL-2 (4-6 doses) or low IL-2 (1-3 doses), for objective response rate (ORR) comparison as a descriptive sensitivity analysis. An unadjusted logistic regression modeled tumor response as a binary outcome with lifileucel-associated eruption occurrence as a binary predictor. Three adjusted models included IL-2 doses (age, sex, and demographic differences) and melanoma-specific factors as covariates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Per retrospective electronic medical health record review, among 44 individuals (34.1% female individuals; mean [SD] age, 54.8 [14.5] years), treated with lifileucel (median, 4.5 IL-2 doses), 22 (50.0%) developed an associated cutaneous eruption while hospitalized, after a median of 4 post-TIL days. Photographs from 14 of 22 individuals (63.6%) with available images demonstrated central-predominant, frequently purpuric morbilliform eruptions. ORRs did not significantly differ by IL-2 stratification (high IL-2: 50.0% vs low IL-2: 37.5%;\n P<\/jats:italic>\n \u2009=\u2009.53). Cutaneous eruption development was associated with a 42-day response across analyses (analysis 1: OR, 7.29; 95% CI, 1.91-27.86;\n P<\/jats:italic>\n \u2009=\u2009.004; OR, 7.65; 95% CI, 1.79-32.69;\n P<\/jats:italic>\n \u2009=\u2009.006; analysis 2: OR, 11.95; 95% CI, 1.90-75.39;\n P<\/jats:italic>\n \u2009=\u2009.008; analysis 3: OR, 9.73; 95% CI, 2.12-44.74;\n P<\/jats:italic>\n \u2009=\u2009.003); 30-day responses were statistically similarly associated. All 90-day cutaneous eruption response analyses did not detect statistical significance.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, lifileucel treatment was frequently complicated by purpuric morbilliform eruptions, which were prognostically favorable and associated with short-term response. The lifileucel-associated eruption may be a peritreatment efficacy marker, assessable during the TIL treatment hospitalization prior to traditional 42-day restaging.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.0605","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:30:31Z","timestamp":1776267031000},"page":"607","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Eruptions and Lifileucel\/Interleukin 2 in Individuals With Metastatic Melanoma"],"prefix":"10.1001","volume":"162","author":[{"given":"Jordan T.","family":"Said","sequence":"first","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakisa","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Medical Oncology, Mass General Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Medical Oncology, Mass General Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Haugh","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Medical Oncology, Mass General Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston"},{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston"},{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Liu","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Cornejo","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Pathology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Cutaneous Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard Data Science Initiative, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"dbr260003r1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"dbr260003r2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study.","author":"Medina","journal-title":"J Clin Oncol"},{"issue":"5","key":"dbr260003r4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-025-00957-5","article-title":"Tumor-infiltrating lymphocyte therapy for the treatment of metastatic melanoma.","volume":"26","author":"Tsai","year":"2025","journal-title":"Am J Clin Dermatol"},{"issue":"16","key":"dbr260003r5","doi-asserted-by":"publisher","first-page":"9594","DOI":"10.1200\/JCO.2024.42.16_suppl.9594","article-title":"Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.","volume":"42","author":"Qi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"dbr260003r6","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma.","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"62","key":"dbr260003r7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee.","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"dbr260003r8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/0190-9622(93)70011-H","article-title":"Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma.","volume":"28","author":"Wolkenstein","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"dbr260003r9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clindermatol.2019.10.006","article-title":"Drug eruptions associated with tumor therapy: Great imitators.","volume":"38","author":"Ludwig","year":"2020","journal-title":"Clin Dermatol"},{"issue":"26","key":"dbr260003r10","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","article-title":"Clinical practice. exanthematous drug eruptions.","volume":"366","author":"Stern","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"dbr260003r11","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1056\/NEJMra2204547","article-title":"Drug reaction with eosinophilia and systemic symptoms.","volume":"391","author":"Kroshinsky","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"dbr260003r12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1001\/jama.2025.13074","article-title":"Cutaneous melanoma: a review.","volume":"334","author":"Joshi","year":"2025","journal-title":"JAMA"},{"issue":"16","key":"dbr260003r13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9607","article-title":"A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.","volume":"41","author":"Olson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"dbr260003r14","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1200\/JCO.2021.39.15_suppl.9537","article-title":"Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor na\u00efve patients with advanced melanoma.","volume":"39","author":"Thomas","year":"2021","journal-title":"J Clin Oncol"},{"key":"dbr260003r15","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206380598250622182719","article-title":"Lifileucel therapy for metastatic melanoma: advancements in tumor-infiltrating lymphocyte-based immunotherapy.","volume":"25","author":"Cherian","year":"2025","journal-title":"Anticancer Agents Med Chem"},{"key":"dbr260003r3","unstructured":"Food and Drug Administration. AMTAGVI (lifileucel) suspension for intravenous infusion: package insert. Published online 2024. Accessed January 28, 2026. https:\/\/www.fda.gov\/media\/176417\/download?attachment"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2847790\/jamadermatology_said_2026_br_260003_1780333363.93132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:00:27Z","timestamp":1781708427000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2847790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0605","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}